ReviewOncology letters2024

Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review).

Mehmet Teomete et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.